Teva Canada has recalled two lots [1] of Pregabalin 150 mg capsules due to possible contamination with the drug sertraline.
This recall is critical because sertraline is an antidepressant that patients may not be prescribed, potentially leading to adverse drug interactions or unexpected side effects.
The company initiated the precautionary measure after routine quality testing detected the possible cross-contamination [2]. Pregabalin is commonly used to treat neuropathic pain and certain types of seizures, while sertraline is a selective serotonin reuptake inhibitor (SSRI) used primarily for depression and anxiety.
Routine testing is designed to ensure that medications contain only the active ingredients listed on the label. When a different pharmaceutical agent is detected, it suggests a failure in the manufacturing or cleaning process, a risk that can occur in facilities producing multiple types of medication.
Health officials in Canada are monitoring the situation to determine the extent of the distribution. Patients using these specific lots are typically advised to consult their healthcare providers for replacement medication to avoid gaps in their treatment.
Teva Canada did not provide specific details regarding the number of affected units beyond the two lots [1]. The company said the recall was a precautionary step to ensure patient safety following the detection of the contaminant [2].
Regulatory bodies oversee these recalls to ensure that contaminated products are removed from pharmacy shelves and patient medicine cabinets. This process involves notifying distributors and pharmacists to track every bottle associated with the flagged lot numbers.
“Teva Canada has recalled two lots of Pregabalin 150 mg capsules.”
Cross-contamination in pharmaceutical manufacturing occurs when residues of one drug are inadvertently introduced into another. In this case, the presence of an antidepressant in a nerve pain medication could pose risks to patients with specific comorbidities or those taking other medications that interact with SSRIs. This event highlights the importance of routine quality control in maintaining the integrity of the generic drug supply chain.
